In brief
Iga Swiatek, the Polish tennis star and reigning French Open champion, has accepted a one-month suspension following a positive test for the prohibited heart medication trimetazidine. The substance was traced to a contaminated medication, with the International Tennis Integrity Agency concluding that she bore no significant fault.
World number two Iga Swiatek has been handed a one-month suspension due to a doping violation after testing positive for trimetazidine, a heart medication. The Polish tennis sensation, who has claimed five Grand Slam titles including four French Opens in the past five years, was provisionally suspended from her tournaments on September 12. This decision was made following an investigation by the International Tennis Integrity Agency (ITIA) which determined the source was from a contaminated regulated medication.Swiatek contested the provisional suspension, asserting that the banned substance originated from a medication manufactured in Poland, her home country. After her appeal was successful on October 4, resulting in the lifting of her provisional ban, the ITIA confirmed that Swiatek was not at fault for the presence of the drug in her system. ITIA chief executive Karen Moorhouse noted that the circumstances of this particular case were unusual, emphasizing that the product, while a regulated substance within Poland, lacks global recognition under the same classification.As a result of the ITIA’s findings, Swiatek’s suspension, originally effective until October, will now allow her eligibility to return by December 4, 2024. This unfortunate event also forced her to forfeit earnings from the Cincinnati Open, where she had reached the semi-finals prior to the doping incident. Consequently, she missed participation in the Korea Open, China Open, and Wuhan Open while the appeal process unfolded. With this ruling, the tennis community waits to see how Swiatek’s career will navigate through the aftermath of this unexpected development.
